How does lactylation-driven ALKBH3 weaken tumor suppressors?
Histone lactylation boosts ALKBH3, which removes m1A from SP100A and diminishes PML nuclear condensates, accelerating ocular melanoma progression.
Source
Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A
Inspect source passages
How does lactylation-driven ALKBH3 weaken tumor suppressors?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Authors report ALKBH3 silencing shows efficient therapeutic efficacy in melanoma in vitro and in vivo.
Therapeutically, the silencing of ALKBH3 exhibits efficient therapeutic efficacy in melanoma both in vitro and in vivo , which could be reversed by the depletion of SP100A.
Abstract frames lactylation-enhanced ALKBH3 as attenuating PML condensates via SP100A m1A removal.
Herein, we found that histone lactylation enhances ALKBH3 expression and simultaneously attenuates the formation of tumor-suppressive promyelocytic leukemia protein (PML) condensates by removing the m 1 A methylation of SP100A, promoting the malignant transformation of cancers.
What they did
Mapped ALKBH3 upregulation under high histone lactylation, identified SP100A as an ALKBH3 m1A target via multiomics, and tested silencing plus YTHDF1 recognition mechanisms in melanoma models.
What they found
ALKBH3 is upregulated in high-risk ocular melanoma with lactylation-linked m1A hypomethylation. Demethylating SP100A impairs PML body formation; ALKBH3 silencing has therapeutic efficacy that SP100A depletion can reverse. YTHDF1 recognizes methylated SP100A transcript.
The limits
What it doesn't show
Does not establish a ready-to-use clinical ALKBH3 inhibitor regimen; ocular melanoma findings may not transfer unchanged to all cancers.
Key terms
- m1A
- N1-methyladenosine RNA modification affecting RNA structure and protein interactions.
- ALKBH3
- m1A demethylase upregulated by histone lactylation in this study.
- Histone lactylation
- Metabolic stress-linked histone mark that boosts ALKBH3 expression here.
- SP100A
- PML-body component whose m1A status supports tumor-suppressive condensates.
- PML condensates
- Nuclear bodies with tumor-suppressor functions disrupted when SP100A is demethylated.
- YTHDF1
- Reader recognizing m1A-methylated SP100A transcript to stabilize/translate it.
Flashcards
0 of 8 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
ALKBH3 expression is boosted by:
Common questions
What boosts ALKBH3?
Excessive histone lactylation in high-risk ocular melanoma.
Key downstream target?
SP100A, a core PML-body component.
Therapeutic hint?
Silencing ALKBH3 works in vitro/in vivo unless SP100A is depleted.
Who reads methylated SP100A?
YTHDF1.
More on Epigenetics